Who Owns Verily?

Verily's sustainability and ethics considerations center on responsible health data management, clinical research ethics, and healthcare accessibility.

Data Privacy and Security: Verily handles sensitive health information and must comply with HIPAA in the United States and GDPR in Europe. The company implements encryption, access controls, and regular security audits. Its data privacy programs include transparent data usage policies and patient consent management. Given its Google heritage, Verily faces heightened scrutiny on data privacy and has invested in building separate, health-specific data infrastructure.

Clinical Research Ethics: Verily's research programs follow institutional review board oversight, informed consent processes, and independent data monitoring committees. The All of Us Research Program and other clinical research initiatives maintain standards for participant safety, data integrity, and transparent reporting.

Healthcare Accessibility: Verily develops solutions aimed at reducing healthcare costs and improving access. Its remote monitoring technologies and preventive care programs are designed to reduce hospital visits and optimize treatment pathways. The partnership with UCHealth and the University of Colorado Anschutz focuses on improving patient outcomes in underserved communities.

Environmental Compliance: Verily's operations comply with environmental regulations for technology companies, including energy efficiency standards for data centers. The company aligns with Alphabet's broader sustainability commitments, though Verily's individual environmental impact is not separately reported.

Supply Chain Responsibility: Verily maintains ethical sourcing practices for its technology products and research equipment. The company's supply chain management includes environmental impact assessments and supplier diversity programs.

Verily has received recognition for its healthcare technology and clinical research contributions:

• NIH Systems Biology Award Extension (2025): $9.2 million two-year renewal from the National Institutes of Health for the FAIRplex platform development, building on the initial 2024 award
• NIH Accelerating Medicines Partnership Award (2024): $4.8 million award for developing data analysis platforms across multiple disease research programs including Alzheimer's, Parkinson's, and autoimmune diseases
• DoD Tradewinds Marketplace Recognition (2026): Verily Pre achieved "Awardable" status in the Department of Defense Tradewinds Solutions Marketplace for government procurement
• Fierce 50 of 2025: Named to Fierce Healthcare's list of innovative healthcare companies
• All of Us Research Program Partnership: Workbench platform supports over 21,500 researchers in the NIH's flagship precision medicine initiative

Verily has faced several challenges since its 2015 founding, primarily related to privacy concerns, project discontinuations, and workforce reductions.

Privacy and Data Security Concerns: Verily's collection and analysis of sensitive health information through Project Baseline and other programs have drawn scrutiny from privacy advocates. The company's affiliation with Google raised questions about whether health data could be used for advertising or other commercial purposes. Verily has responded by building separate data infrastructure and implementing strict data isolation policies, but the Google association remains a source of public concern.

Smart Contact Lens Project Failure: Verily's smart contact lens project, developed with Novartis to measure glucose levels in tears for diabetes management, was discontinued after Novartis ended the partnership in 2018. The project's failure raised questions about Verily's ability to bring complex medical devices to market and represented a significant setback for its wearable technology ambitions.

2023 Workforce Reduction: Verily laid off approximately 15% of its staff in January 2023, cutting roughly 240 employees. The restructuring reflected broader cost discipline across Alphabet and the technology sector. The layoffs affected morale and raised concerns about the company's growth trajectory, though management characterized the cuts as a necessary refocusing on commercial priorities.

Business Divestitures: Verily divested several businesses under Gillett's leadership, including Granular, its insurance subsidiary. While these divestitures streamlined operations, they also represented abandoned strategic bets that had consumed significant investment.

Commercial Viability Questions: Verily has operated within Alphabet's Other Bets segment, which collectively generates operating losses. The company's transition from research projects to revenue-generating commercial products has taken longer than initially anticipated. The March 2026 funding round and transition to independence partially address these concerns by bringing in outside investors and imposing market discipline.